Gilead Sciences | GILD - Zahlungsmittel Und Äquivalente

Aktienkurs
139.37
Täglich Wechseln
3.03 2.22%
Monatlich
-7.11%
Jährlich
25.24%
Q2 Prognose
130.22




Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 5.23B 400M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
J&J USD 19.71B 1.48B 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
United Therapeutics USD 1.56B 217M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12